Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose IL-2 in COVID-19-related ARDS (LILIADE-COVID)
2020-001571-32Phase 2Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) comparing Low-dose interleukin-2 with Placebo (2 arms). Primary endpoint: PaO2/FiO2 ratio at Day 7. Started Apr 2020; status: terminated.
02
Drugs
aldesleukin
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2020-001571-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001571-32.